BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33965185)

  • 1. Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation.
    Salas MQ; Atenafu EG; Law AD; Lam W; Pasic I; Chen C; Dong Hwan Kim D; Michelis FV; Gerbitz A; Lipton JH; Mattsson J; Kumar R; Viswabandya A
    Transplant Cell Ther; 2021 May; 27(5):428.e1-428.e9. PubMed ID: 33965185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
    Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
    Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.
    Wang Y; Wu DP; Liu QF; Xu LP; Liu KY; Zhang XH; Yu WJ; Xu Y; Huang F; Huang XJ
    J Hematol Oncol; 2019 Sep; 12(1):88. PubMed ID: 31481121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
    Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
    Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
    Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.
    Li X; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Tong Y; Dong B; Wan L; Song X
    Front Immunol; 2023; 14():1252879. PubMed ID: 37954615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia.
    Nagler A; Kanate AS; Labopin M; Ciceri F; Angelucci E; Koc Y; Gülbas Z; Arcese W; Tischer J; Pioltelli P; Ozdogu H; Afanasyev B; Wu D; Arat M; Peric Z; Giebel S; Savani B; Mohty M
    Haematologica; 2021 Jun; 106(6):1591-1598. PubMed ID: 32354866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
    Soltermann Y; Heim D; Medinger M; Baldomero H; Halter JP; Gerull S; Arranto C; Passweg JR; Kleber M
    Ann Hematol; 2019 Jun; 98(6):1485-1493. PubMed ID: 30915500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia.
    Salas MQ; Chen S; Lam W; Pasic I; Gerbitz A; Michelis FV; Kim DDH; Al-Shaibani Z; Lipton JH; Mattsson J; Kumar R; Viswabandya A; Law AD
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1511-1519. PubMed ID: 32422253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical Cord Blood Transplantation with 8 mg/kg Antithymocyte Globulin as Graft-versus-Host Disease Prophylaxis Compared to Haploidentical Transplantation with 10 mg/kg Antithymocyte Globulin in the Treatment of Acute Leukemia.
    Yuan F; Li G; Li M; Wei X; Fu Y
    Transplant Cell Ther; 2023 Dec; 29(12):771.e1-771.e10. PubMed ID: 37748539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia.
    Salas MQ; Prem S; Atenafu EG; Law AD; Lam W; Al-Shaibani Z; Loach D; Kim DDH; Michelis FV; Lipton JH; Kumar R; Mattsson J; Viswabandya A
    Eur J Haematol; 2019 Nov; 103(5):510-518. PubMed ID: 31449699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
    Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.
    Nagler A; Labopin M; Dholaria B; Niittyvuopio R; Maertens J; Poiré X; Cornelissen J; Reményi P; Bourhis JH; Beguin Y; Malladi R; Kerre T; Schroyens W; Savani BN; Mohty M
    Blood Adv; 2019 Jul; 3(13):1950-1960. PubMed ID: 31262738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation.
    Mountjoy L; Jain T; Kunze KL; Khera N; Sproat LZ; Jennifer W; McCallen M; Leis JF; Noel P; Slack JL; Palmer J
    Leuk Lymphoma; 2020 Aug; 61(8):1996-2002. PubMed ID: 32281491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.